213 related articles for article (PubMed ID: 17659921)
1. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
[TBL] [Abstract][Full Text] [Related]
2. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.
Ray MJ; Juneja M; Bett N; Walters DL
EuroIntervention; 2009 Aug; 5(3):330-5. PubMed ID: 19736157
[TBL] [Abstract][Full Text] [Related]
3. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention.
Sibbing D; Busch G; Braun S; Jawansky S; Schömig A; Kastrati A; Ott I; von Beckerath N
Eur Heart J; 2008 Jun; 29(12):1504-9. PubMed ID: 18467322
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial.
Khanna V; Shahzad A; Thayalasamy K; Kemp I; Mars C; Cooper R; Roome C; Wilson K; Harris S; Stables R; Curzen N
Thromb Res; 2018 Dec; 172():36-43. PubMed ID: 30359789
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.
Pepke W; Eisenreich A; Jaster M; Ayral Y; Bobbert P; Mayer A; Schultheiss HP; Rauch U
Cardiovasc Ther; 2013 Apr; 31(2):115-23. PubMed ID: 22212466
[TBL] [Abstract][Full Text] [Related]
8. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin.
Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2006; 118(3):361-9. PubMed ID: 16139336
[TBL] [Abstract][Full Text] [Related]
10. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention.
Aggarwal A; Sobel BE; Schneider DJ
J Thromb Thrombolysis; 2002 Jun; 13(3):161-5. PubMed ID: 12355033
[TBL] [Abstract][Full Text] [Related]
11. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention.
Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
Coron Artery Dis; 2005 Sep; 16(6):401-5. PubMed ID: 16118546
[TBL] [Abstract][Full Text] [Related]
12. High-shear- and-thrombin-inducible platelet adhesion and aggregation in patients undergoing percutaneous coronary intervention. Effects of unfractionated heparin versus bivalirudin.
Eslam RB; Reiter N; Kaider A; Lang IM; Panzer S
Thromb Haemost; 2011 Mar; 105(3):496-500. PubMed ID: 21174001
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction.
Chu WW; Kuchulakanti PK; Wang B; Torguson R; Clavijo LC; Pichard AD; Suddath WO; Satler LF; Kent KM; Waksman R
Cardiovasc Revasc Med; 2006; 7(3):132-5. PubMed ID: 16945819
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention.
Busch G; Steppich B; Sibbing D; Braun SL; Stein A; Groha P; Schömig A; Kastrati A; von Beckerath N; Ott I
Thromb Haemost; 2009 Feb; 101(2):340-4. PubMed ID: 19190819
[TBL] [Abstract][Full Text] [Related]
15. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
Fiedler KA; Ndrepepa G; Schulz S; Floh S; Hoppmann P; Kufner S; Bernlochner I; Byrne RA; Schunkert H; Laugwitz KL; Kastrati A
EuroIntervention; 2016 Feb; 11(11):e1275-82. PubMed ID: 26865445
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
Saucedo JF; Aude W; Pacheco R; Thorn B; Matin Z; Husain K; Garza L
Am J Cardiol; 2005 Jun; 95(12):1453-6. PubMed ID: 15950569
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.
Kimmelstiel C; Zhang P; Kapur NK; Weintraub A; Krishnamurthy B; Castaneda V; Covic L; Kuliopulos A
Circ Cardiovasc Interv; 2011 Apr; 4(2):171-9. PubMed ID: 21364148
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.
Frere C; Laine M; Lemesle G; Morange PE; Paganelli F; Dignat-George F; Resseguier N; Guieu R; Camoin-Jau L; Bonello L
Platelets; 2019; 30(1):105-111. PubMed ID: 29172822
[TBL] [Abstract][Full Text] [Related]
19. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Furman MI; Krueger LA; Linden MD; Fox ML; Ball SP; Barnard MR; Frelinger AL; Michelson AD
J Thromb Haemost; 2005 Feb; 3(2):312-20. PubMed ID: 15670038
[TBL] [Abstract][Full Text] [Related]
20. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
Ndrepepa G; Schulz S; Keta D; Mehilli J; Birkmeier A; Massberg S; Laugwitz KL; Neumann FJ; Seyfarth M; Berger PB; Schömig A; Kastrati A
Am J Cardiol; 2010 Jan; 105(2):163-7. PubMed ID: 20102912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
